Efficacy and safety of low-dose telitacicept in IgA nephropathy: a real-world study

Clicks: 18
ID: 332158
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #131 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background IgA nephropathy (IgAN) represents one of the most common causes of primary glomerulonephritis with unmet clinical needs. This study evaluates the efficacy and safety of telitacicept in patients with IgAN. Methods This real-world study included 38 biopsy-proven IgAN patients with baseline estimated glomerular filtration rate (eGFR) > 10 mL/min/1.73 m² and urine protein-to-creatinine ratio (UPCR) > 440 mg/g. Nineteen patients received weekly telitacicept 80mg (telitacicept group), divided into early-start (telitacicept treatment initiated within 6 months after diagnosis) and late-start (>6 months) subgroups. The other 19, diagnosed during the same period but not receiving telitacicept, served as controls. Clinical data were collected over 12 months. Safety was evaluated. Results Baseline characteristics were comparable between groups. In the telitacicept group, median UPCR was 1715.98 mg/g (IQR: 1281.63–2892.11) and median eGFR was 45.45 mL/min/1.73 m² (IQR: 33.86–93.14). Over 12 months, telitacicept 80 mg weekly was associated with a trend toward greater proteinuria reduction (−51.52% versus − 33.31%, P = .081) and a favorable change in renal function (+1.77 versus -4.06 mL/min/1.73 m², P = .008). The early-start subgroup showed greater benefits than the late-start subgroup. In an exploratory analysis of patients with eGFR below 35 mL/min/1.73 m² (n = 7 each), telitacicept treatment yielded a sustained reduction in UPCR (−48.83% versus + 9.68%) and a stable mean annualized eGFR slope (+0.77 versus − 8.88 mL/min/1.73 m²) over 12 months. No severe adverse events occurred with telitacicept, versus one in controls. Conclusions Our study supports the potential efficacy of low-dose telitacicept in reducing proteinuria and stabilizing eGFR in IgAN. Its clinical benefits were more pronounced when initiated early after diagnosis. Furthermore, in IgAN patients with severe renal impairment, telitacicept may yield better outcomes for proteinuria reduction and eGFR preservation than conventional treatment. These advantages position low-dose telitacicept as a potentially effective treatment strategy, though larger prospective studies are warranted.
Reference Key
openalex_W7221574346 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chenxi Liu, Juanyong Zhao, Ming Xing Xia, Xinyan Fan, Xunzi Tang, Xiaomiao Hao, Lili Wan, Bin Len, Di Liu, Haiyang Liu, Linshan Zhou, Xia Tan, Hong Liu
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag312
URL
https://doi.org/10.1093/ckj/sfag312
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.